NICHOLAS DRESSEL: Open Payments
NPI 1285110494 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$873 in 54 payments from 17 companies in 2025. Trend: 2023 $1,727 · 2024 $1,675 · 2025 $873
Food & beverage: $873
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 11 | $240 |
| Amgen Inc. | 14 | $137 |
| Novo Nordisk Inc | 5 | $81 |
| GlaxoSmithKline, LLC. | 4 | $76 |
| SANOFI PASTEUR INC. | 2 | $57 |
| Gilead Sciences, Inc. | 2 | $48 |
| PFIZER INC. | 2 | $35 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| Renalytix AI, Inc. | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $22 |
Products named: ZEPBOUND, MOUNJARO, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, OTEZLA, Ozempic, TRELEGY ELLIPTA, Wegovy.
Industry payments across TX — which companies pay providers there.
